妊娠期使用赫赛汀(曲珠单抗)治疗发生可逆性无羊水  

Herceptin (trastuzumab) therapy during pregnancy:Association with reversible anhydramnios

作　　者：Watson W.J. 王伟华 

机构地区：[1]Dr.Division of Maternal Fetal Medicine, Department of Obstetrics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States

出　　处：《世界核心医学期刊文摘（妇产科学分册）》2005年第8期61-62,共2页Core Journal in Obstetrics/Gynecology

摘　　要：BACKGROUND: Herceptin (trastuzumab), a new achemotherapeutic agent, is a monoclonal antibody that blocks the human epidermal growth factor receptor 2 protein. There is no reported experience with use of this agent during pregnancy and possible effects on the fetus. CASE: A patient with breast cancer was treated with Herceptin during pregnancy. This treatment was associated with anhydramnios, which resolved slowly after the drug was discontinued. CONCLUSION: Although listed as a category B drug, experience with Herceptin in human pregnancy is limited, and it should be used with caution. Investigation of the role of human epidermal growth factor receptor 2 protein in the embryonic kidney may further our understanding of amniotic fluid dynamics.BACKGROUND: Herceptin (trastuzumab), a new achemotherapeutic agent, is a monoclonal antibody that blocks the human epidermal growth factor receptor 2 protein. There is no reported experience with use of this agent during pregnancy and possible effects on the fetus. CASE: A patient with breast cancer was treated with Herceptin during pregnancy. This treatment was associated with anhydramnios, which resolved slowly after the drug was discontinued. CONCLUSION: Although listed as a category B drug, experience with Herceptin in human pregnancy is limited, and it should be used with caution. Investigation of the role of human epidermal growth factor receptor 2 protein in the embryonic kidney may further our understanding of amniotic fluid dynamics.

关 键 词：赫赛汀 谨慎使用 化疗药物 单克隆抗体 水动力学 

分 类 号：R714.2[医药卫生—妇产科学]